Innovation Voucher INNOSUP - Horizon 2020 Permides
PoC Device for Personalized Sepsis Management
Pharma Beneficiary - Alifax Research & Development srl (Italy)
IT Solution Providers - BioSistemika (Slovenia)
Every year, 30 million people are affected by sepsis resulting in 6-9 million deaths globally, most of which preventable with rapid and effective treatment. Phenotypic tests,
the current standard, need longer times to identify the pathogen and its susceptibility to antibiotics. On the other side, genotypic tests are quite expensive and require
qualifi ed staff.
We are going to apply our innovative technology for rapid qPCR to create a robust diagnostic Point of Care (PoC) device for the genotyping of sepsis-causing pathogens
and their antibiotics’ vulnerability. The proposed SMart of IT project aims to develop an integrated software platform and a corresponding mobile app. Its application will assure an effective translation of experimental data into a signifi cant clinical report that will immediately be available to clinician and shared with the medical team allowing for prompt personalized treatment.
more info Permides.eu